What Would You Do in the Case of a Virus Breakout in Your Manufacturing Plant?
Contributor:
Pharma IQ
Posted: 09/01/2010 12:00:00 AM EDT | 0
Posted: 09/01/2010 12:00:00 AM EDT | 0
|
The porcine circovirus contamination of GSK’s Rotarix vaccine in March of this year, and previous contaminations in both Baxter and Genzyme biological products in 2009, have highlighted the issue of viral safety in biologics more than ever before. In a recent interview Dr. Mark Plavsic, Senior Director, Gene Therapy Development Genzyme, spoke with Andrea Charles from Pharma IQ, about the latest techniques ...
-
Will SDMS Become ELN of the Future? -
Boosting Bioavailability Through Partnerships -
For Disaster Plans to be Effective, They Must be Dynamic -
Implementing Thermal Processing Technologies for the Production of Amorphous Solid Dispersions -
GMP Guidelines -
Improving Hospital Efficiency Through Technology -
Career Spotlight: Pharma Regulatory Affairs -
Evaluating Biomarkers for Cancer Screening -
Career Spotlight: Clinical Research Coordinator -
GCP Guidelines
* = required.
Not a member yet? Sign up
You Should Check Out:
Events of Interest
-
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now -
Exploring Challenges and Opportunities in Predictive Safety Tools: Trends from Industry-Wide Surveys
January 13, 2012
Register Now -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
March 28, 2012
Register Now -
Use of Cardiac Safety Data in Early Phase Trials to Supplement or Replace a Thorough QT Trial
June 11, 2012
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!